THE US FDA has granted
accelerated approval for Keytruda
(pembrolizumab) to treat patients
with advanced non-small cell
lung cancer whose disease has
progressed after other treatments,
and with tumours that express a
protein called PD-L1.
Keytruda has been approved for
use with a companion diagnostic,
the PD-L1 IHC 22C3 pharmDx test,
the first test designed to detect
PD-L1 expression in non-small cell
lung tumours.The above article was sent to subscribers in Pharmacy Daily's issue from 06 Oct 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Oct 15
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.